Welcome To Stuart Therapeutics
Stuart Therapeutics, established in 2017 is developing PolyCol, a unique therapeutic platform that offers improvements in health outcomes for a wide variety of medical and veterinary conditions.
PolyCol is based on patented research from a major U.S. university, combined with additional intellectual property developed by Stuart Therapeutics. The company has developed applications for PolyCol in treating certain ophthalmic, gastrointestinal, inflammatory, and oncology conditions.
The initial product under development that takes advantage of PolyCol is ST-100, the first therapeutic for dry eye syndrome that addresses both the immediate painful symptoms, as well as the underlying inflammatory causes.
Stuart Therapeutics’ first drug candidate is ST-100, a novel therapeutic in drop formulation for Dry Eye Disease (DED). Unlike most therapeutic solutions for DED, ST-100 is a fast acting, broadly applicable option for patients that has shown an ability to provide complete corneal healing in less than 24 hours in animal studies. ST-100 is believed to act by directly healing and aligning exposed and damaged collagen fibers in moderate to severe DED sufferers, providing an ideal environment for epithelial recovery and relief from painful symptoms.
STUART, FLORIDA June 12, 2019: Stuart Therapeutics, Inc. (STUART), an innovative pre-clinical ophthalmic therapeutic development company, today announces it has entered into a strategic partnership with Ora®, Inc. (“ORA”), the premier global ophthalmology contract research organization. ORA is investing in its partnership with STUART by providing CMC program execution, IND preparation, and related strategic consulting
April 22nd, 2019, Stuart, Florida For Immediate Release Stuart Therapeutics, Inc., a pre-clinical stage life sciences company developing solutions for difficult to treat ophthalmic diseases, today announced positive results from in vitro experiments using its proprietary collagen mimetic peptide (CMP), PolyColTM (PolyCol) to probe applicability for conditions associated with dry age-related macular degeneration (Dry AMD).
Stuart Therapeutics Receives Positive Response in Pre-IND Meeting with FDA for its Dry Eye Disease Therapeutic Candidate, ST-100
April 3rd, 2019, Stuart, Florida For Immediate Release Stuart Therapeutics, Inc. (Stuart), a pre-clinical stage company developing advanced ophthalmic therapeutics, announced today that it has successfully completed a pre-IND meeting regarding the development plan for ST-100, Stuart’s first drug candidate for Dry Eye Disease (DED). The meeting, held with the Food and Drug Administration’s Center